Six Sigma in Pharmaceutical Regulatory Affairs and Manufacturing: A Comprehensive Review
Kalyani B. Pawar*, Suraj M. Patil, Tejas E. Patil, Amol R. Pawar, Pankaj S. Patil,
Vikas V. Patil, Kalpesh Kumar. S. Wagh
Department of Pharmaceutical Quality Assurance, [Kisan Vidya Prasarak Sansta’S,
Institute of Pharmaceutical Education Boradi, 42542], Maharastra, India.
*Corresponding Author E-mail: amolpharma9@gmail.com
ABSTRACT:
The pharmaceutical industry occupies a unique position among manufacturing sectors. The product it supplies is intended to act on human physiology, frequently at very low doses and over prolonged periods, and any deviation in identity, strength, purity or quality can translate directly into patient harm. For this reason, pharmaceutical manufacturing is one of the most heavily regulated activities in the modern economy, governed by statutory frameworks such as 21 CFR Parts 210 and 211 in the United States, EudraLex Volume 4 in the European Union, and the harmonised guidelines of the International Council for Harmonisation (ICH) 1–3.
Against this backdrop, the management discipline of Six Sigma has become an increasingly visible feature of pharmaceutical operational strategy. Six Sigma is a structured, statistically grounded approach to reducing process variability and eliminating defects 4,5. Its quantitative target—no more than 3.4 defects per million opportunities (DPMO) at the six-sigma level—provides an unusually concrete benchmark against which a process can be evaluated, and its problem-solving cycles, DMAIC (Define, Measure, Analyse, Improve, Control) and DMADV (Define, Measure, Analyse, Design, Verify), supply a common language for cross-functional improvement teams 6.
The fit between Six Sigma and pharmaceutical quality management is, in principle, very close. Regulatory expectations articulated in ICH Q8(R2), Q9 and Q10 emphasise a scientific and risk-based understanding of products and processes, a lifecycle approach to quality, and the use of formal tools for risk assessment and continual improvement 7–9. These expectations map directly onto the Six Sigma toolbox, which incorporates failure mode and effects analysis (FMEA), statistical process control (SPC), root-cause analysis (RCA), design of experiments (DoE) and process-capability assessment. Several authors have argued that Six Sigma, properly implemented, is the operational vehicle through which the ICH Q-trilogy is delivered on the shop floor 10,11.
Despite this conceptual alignment, the migration of Six Sigma into pharmaceutical operations has not been entirely smooth. The discrete-event manufacturing logic of automotive or electronics production does not transfer directly to batch chemistry, biological cell culture or sterile fill-finish operations, where process understanding is often incomplete and the cost of failed experimentation is high. Regulatory cycle times, the heterogeneity of pharmaceutical processes, and a corporate culture historically focused on compliance rather than continuous improvement have all moderated the pace of adoption 12. The emergence of Lean Six Sigma—which couples the variation-reduction logic of Six Sigma with the waste-elimination logic of Lean manufacturing—has helped bridge this gap by offering a more flexible, value-stream-oriented framework that fits the realities of pharmaceutical batch production 13.
The Greek letter sigma (σ) denotes the standard deviation of a population and serves as the conventional measure of variability in statistical analysis. In the Six Sigma framework, the “sigma level” of a process is defined as the number of standard deviations that fit between the process mean and the nearer specification limit, after allowance for the empirical 1.5-σ long-term drift that Motorola engineers observed in operating processes 14. Table 1 illustrates the relationship between sigma level, yield and DPMO.
Process capability is summarised by the indices Cp and Cpk. Cp expresses the ratio of the specification width to six process standard deviations and reflects the potential capability if the mean is perfectly centred; Cpk, which incorporates the proximity of the process mean to the nearer specification limit, captures the actual capability of the process as it currently runs 15. A Cpk ≥ 1.33 is typically regarded as the minimum acceptable for routine pharmaceutical operations, while values approaching 2 correspond to genuinely six-sigma performance. These indices are also used as objective acceptance criteria in design-space verification under ICH Q8 and in continued process verification under stage 3 of the FDA process-validation guidance 16.
Six Sigma was formalised at Motorola in 1986 by Bill Smith as a response to escalating warranty costs in semiconductor manufacturing, and was credited with multi-billion-dollar savings during the 1990s when adopted by General Electric, AlliedSignal and other industrial conglomerates 17. Its translation into healthcare and pharmaceuticals began in the early 2000s, initially in hospital operations and only later in regulated manufacturing. Early case studies in pharmaceutical companies focused on reducing batch failures, deviations and the cost of poor quality (COPQ), and demonstrated that the techniques—though originally industrial—could be productively applied to regulated batch processes when adapted appropriately 18,19.
Several features distinguish Six Sigma from earlier quality movements such as Total Quality Management. First, it is rigorously data-driven: decisions are required to be justified by statistical analysis of empirical measurements rather than by anecdote or expert opinion. Second, it is structured: the DMAIC and DMADV frameworks impose a uniform problem-solving discipline across the organisation, which simplifies cross-functional collaboration and external audit. Third, it is project- and outcome-oriented: each Six Sigma initiative is scoped as a discrete project with measurable financial or quality goals and a defined sponsor. Fourth, it places the customer (whether external or internal) at the centre of the definition of value, expressed through tools such as Voice of the Customer (VOC) and Critical-to-Quality (CTQ) trees. Fifth, it depends on a structured training and certification system—Yellow, Green, Black and Master Black Belt levels—that institutionalises the methodology within the organisation 20.
Fig 1. Six sigma quality scale
Table 1. Relationship between sigma level, defects per million opportunities (DPMO) and process yield, after allowing for the conventional 1.5-σ long-term shift.
|
Sigma level |
DPMO |
Yield (%) |
Practical interpretation |
|
2σ |
308,537 |
69.15 |
Generally unacceptable for any regulated process |
|
3σ |
66,807 |
93.32 |
Typical of unimproved processes; large COPQ |
|
4σ |
6,210 |
99.38 |
Industry average for many sectors |
|
5σ |
233 |
99.977 |
Best-in-class manufacturing performance |
|
6σ |
3.4 |
99.99966 |
World-class; target for critical pharmaceutical processes |
Six Sigma is operationalised through two complementary improvement frameworks: DMAIC, used to improve existing processes that are failing to meet specification, and DMADV (also known as Design for Six Sigma, DFSS), used to design new processes or products to a defined six-sigma capability from the outset 21. Both follow a sequential, gated structure in which each phase produces deliverables that must be reviewed before the next phase begins.
The Define phase scopes the problem, articulates its impact on patient or business outcomes, and secures the resources to address it. Typical deliverables include the project charter (problem statement, goal statement, scope, team and timeline), a high-level process map in SIPOC form (Suppliers–Inputs–Process–Outputs–Customers), an explicit statement of the Voice of the Customer, and the CTQ characteristics that translate customer expectations into measurable process outputs.
The Measure phase establishes the current performance of the process. Detailed process maps are drawn, key process input and output variables (KPIVs and KPOVs) are identified, and an operational definition is fixed for each. A measurement-system analysis (MSA), typically a Gauge R&R study, is performed to verify that the measurement system itself is fit for the intended decisions. A baseline data-collection plan is then executed, and the process capability is computed 22.
In the Analyse phase, the team identifies the root causes of poor performance. Tools commonly employed include Pareto analysis to prioritise defect categories, Ishikawa (fishbone) diagrams to enumerate candidate causes, hypothesis testing (t-tests, ANOVA, chi-square) to test their effects statistically, and regression analysis to model relationships between KPIVs and KPOVs. The output is a short, evidence-based list of vital few causes that drive the observed defects 23.
The Improve phase generates, evaluates and implements counter-measures. Design of experiments (DoE) is the principal quantitative tool, allowing several factors to be evaluated simultaneously with a minimum number of runs and explicit estimation of interaction effects. Failure mode and effects analysis (FMEA) is used to anticipate the risks introduced by the proposed changes, while error-proofing techniques (poka-yoke) and visual management are used to make the new process robust against operator variability 24.
The Control phase ensures that the gains achieved are sustained. Standard operating procedures (SOPs) are updated, training is delivered, and a control plan is established that specifies, for each KPIV and KPOV, the response, the sampling plan, the control chart and the reaction plan. The process is then handed back to its owner, with appropriate metric reporting cadence and management review. The phase often concludes with formal recognition of financial benefits by the finance function, which both validates the project and reinforces organisational commitment to the methodology 25.
DMADV is applied when an existing process is fundamentally incapable of meeting requirements, when a new product or process is being designed, or when an existing process is to be re-engineered from the ground up. The Define and Measure phases mirror those of DMAIC, focusing on customer requirements and CTQs. In the Analyse phase, multiple design alternatives are generated and screened using tools such as Pugh selection matrices and quality function deployment (QFD). The Design phase produces a detailed, parameterised design ready for pilot construction, often using DoE to optimise design parameters. The Verify phase confirms that the realised design meets the original CTQs through pilot testing and statistical validation, after which the design is transferred to operations 26.
Lean Six Sigma integrates the variation-reduction logic of Six Sigma with the waste-elimination logic of Lean manufacturing as articulated in the Toyota Production System 27. Lean defines value strictly from the customer’s perspective and seeks to eliminate any activity that does not contribute to value—commonly summarised as the seven wastes (overproduction, waiting, transportation, over-processing, inventory, motion and defects), to which an eighth, under-utilisation of human talent, is now often added 28.
Table 3. The seven categories of waste recognised in Lean Six Sigma and their typical manifestations in pharmaceutical operations.
|
Waste |
Definition |
Typical pharmaceutical manifestation |
|
Overproduction |
Producing more or earlier than required |
Speculative batch making; building stock beyond demand |
|
Waiting |
Idle time between value-adding steps |
Quality-control release queues; equipment changeover idle time |
|
Transportation |
Unnecessary movement of materials |
Multiple inter-building transfers of intermediates |
|
Over-processing |
Doing more work than the specification requires |
Duplicate sampling; redundant in-process tests |
|
Inventory |
Materials held in excess of need |
WIP between unit operations; raw-material safety stock |
|
Motion |
Unnecessary movement by people or equipment |
Operator travel between distant work stations |
|
Defects |
Output that fails to meet specification |
Batch rejections, deviations, recalls |
|
Under-utilised talent |
Failure to use staff knowledge and skill |
Operators excluded from improvement decisions |
A brief description of the most important tools follows; their typical application phase and pharmaceutical relevance are summarised in Table 4.
SPC is the discipline of monitoring a process over time using statistical charts that distinguish common-cause variation (inherent to the process) from special-cause variation (assignable to a specific event) [29]. Shewhart charts for variables data (e.g., X-bar/R, X-bar/S, I-MR) and for attribute data (p, np, c, u) are standard. In pharmaceutical operations.
4.2 Pareto Analysis:
Pareto analysis applies the 80/20 principle to defect data: a small number of categories typically accounts for the majority of failures, and improvement effort should be concentrated on the “vital few.” The Pareto chart, a bar chart of defect frequencies sorted in decreasing order with an overlaid cumulative percentage, is one of the most widely used tools in the Analyse phase of DMAIC and in CAPA prioritisation 30.
FMEA is a structured method for identifying the ways in which a process or design may fail, the consequences of each failure, and the actions necessary to mitigate the highest-priority risks. Severity, occurrence and detectability are scored, typically on a 1–10 scale, and combined into a Risk Priority Number (RPN). FMEA is explicitly recommended in ICH Q9 as a quality risk management tool and is widely used in pharmaceutical development, manufacturing, validation and CAPA 31.
RCA encompasses a family of techniques—the 5-Whys, fishbone (Ishikawa) diagrams, fault-tree analysis, current-reality trees—whose purpose is to trace an observed defect back to its underlying cause rather than its proximate symptom. Robust RCA is a regulatory expectation in deviation and complaint investigations, and inadequate RCA is one of the most common findings on FDA Form 483 observations and EMA inspection reports 32.
DoE is the systematic, statistical planning of experiments to model the relationship between input factors and output responses with maximum information for a given number of runs. Screening designs (fractional factorial, Plackett–Burman) identify the most influential factors; response-surface designs (central composite, Box–Behnken) map the optimum operating region; and mixture designs handle formulations whose components are constrained to sum to a fixed total 33.
VSM, inherited from Lean, is a graphical representation of all material and information flows required to bring a product from raw material to the customer. It distinguishes value-adding from non-value-adding steps and quantifies process lead time, cycle time and inventory. VSM is particularly powerful in pharmaceutical contexts where cycle time is dominated by quality holds, documentation handovers and equipment changeovers rather than by transformation time 34.
Table 4. Principal Six Sigma tools, their phase of application within DMAIC and representative pharmaceutical uses.
|
Tool |
DMAIC phase |
Pharmaceutical application |
|
SIPOC, VOC, project charter |
Define |
Scoping CAPA and improvement projects |
|
Process map, MSA, Gauge R&R |
Measure |
Validating analytical and in-process measurement systems |
|
SPC, control charts |
Measure / Control |
In-process control; continued process verification |
|
Pareto analysis |
Analyse |
Prioritising deviation categories |
|
Fishbone, 5-Whys |
Analyse |
Deviation and complaint root-cause investigation |
|
FMEA |
Analyse / Improve |
ICH Q9 risk assessment; CAPA prioritisation |
|
Design of experiments (DoE) |
Improve / Design |
Formulation and process optimisation; design space |
|
Value-stream mapping |
Define / Analyse |
Reducing batch cycle time and WIP |
|
Standard work, poka-yoke, 5S |
Improve / Control |
Operator-error reduction; GMP workplace organisation |
|
Control plans, SOPs |
Control |
Sustaining gains under GMP |
|
Process capability (Cp, Cpk) |
Measure / Control |
Demonstrating capability for design-space verification |
Pharmaceutical manufacturing is dominated by batch chemistry and unit operations such as crystallisation, granulation, compression, coating, fill-finish and lyophilisation. Each unit operation introduces variation that ultimately propagates to the finished product. Reported case studies demonstrate that Six Sigma applied to granulation has reduced the coefficient of variation of in-process moisture content and tablet weight, while application to tablet compression has decreased the rate of weight, hardness and friability deviations 35,36.
Pharmaceutical R&D consumes a substantial fraction of corporate budgets and is characterised by long timelines and high attrition. DFSS / DMADV approaches have been applied to formulation development, where designed experiments replace one-factor-at-a-time experimentation and allow systematic identification of the design space 37.
Reducing manufacturing and release cycle times has direct commercial and regulatory implications: faster release reduces inventory cost and time-to-patient, while shorter campaign times improve plant utilisation. Lean Six Sigma projects in pharmaceutical operations have repeatedly demonstrated reductions of 20–50% in batch-release cycle time, achieved primarily by eliminating documentation queues, parallelising QC testing and reducing redundant sampling 38.
The cost of poor quality—comprising internal failure (rework, rejected batches), external failure (recalls, complaints), appraisal (testing) and prevention costs—is typically 15–25% of revenue in pharmaceutical companies that have not implemented systematic improvement programmes 39.
CAPA is an explicit regulatory requirement under 21 CFR 820 for devices and 21 CFR 210/211 (and EU GMP Chapter 1) for medicinal products. Inadequate CAPA is a recurring theme in FDA warning letters [40]. Several authors have argued that DMAIC, properly instantiated, is essentially a CAPA process with statistical underpinnings, and have proposed DMAIC-based CAPA templates that combine regulatory rigour with the variation-reduction focus of Six Sigma 41.
Outside manufacturing, Six Sigma is now widely applied within hospital and ambulatory healthcare to improve medication safety, reduce dispensing errors, shorten emergency-department length of stay and improve infection-control metrics 42.
Despite a strong conceptual fit, Six Sigma implementation in pharmaceutical organisations frequently underperforms expectations. Recurring obstacles can be grouped into five categories.
First, cultural resistance is pervasive. Pharmaceutical quality functions historically prioritise compliance and conservatism, and may regard statistical improvement initiatives as a threat to validated states rather than a complement to them. Sustained change requires visible leadership commitment, clear linkage between Six Sigma projects and regulatory or financial outcomes, and recognition of the role of frontline operators as a source of process knowledge.
Second, data infrastructure is often inadequate. SPC and DoE depend on clean, time-stamped, contextualised data, but pharmaceutical environments still rely heavily on paper batch records and on data fragmented across disparate computerised systems. Without unified electronic batch records, manufacturing execution systems and laboratory information management systems, Six Sigma projects spend disproportionate time on data extraction and cleaning 43.
Third, regulatory caution can slow the implementation of improvements. Process changes affecting validated parameters typically require formal change control and may require regulatory notification or approval. Without the mechanisms introduced by ICH Q12 (established conditions, post-approval change management protocols), even well-justified Six Sigma improvements may stall in the variation pipeline.
Fourth, the heterogeneity of pharmaceutical processes complicates the generalisation of improvements. A DoE conducted on one product line may not be readily transferable to another, and the relatively small number of batches per campaign limits the statistical power available for SPC.
Fifth, sustainability of gains is a persistent issue. Improvement projects that lack a robust control plan, ongoing metric reporting and management review tend to regress within months of project closure 44.
Several developments are likely to reshape Six Sigma practice in pharmaceutical operations over the next decade. The accelerating adoption of Process Analytical Technology (PAT) provides real-time, in-line measurement of critical quality attributes, multiplying both the volume and the timeliness of data available to SPC and DoE. Continuous manufacturing of solid oral dosage forms, oligonucleotides and biologics removes the batch-to-batch discretisation that has historically constrained statistical analysis and enables tighter control loops 45,46.
Industry 4.0 technologies—cloud-based manufacturing execution systems, the industrial Internet of Things, digital twins and edge computing—are progressively eliminating the data-infrastructure bottleneck described above. Machine-learning techniques are being applied to large historical datasets to perform automated root-cause analysis, to detect drifts that conventional Shewhart rules miss, and to generate predictive models of in-process quality 47.
Six Sigma, and in particular its hybridised form Lean Six Sigma, offers the pharmaceutical industry a coherent, statistically grounded framework for reducing variation, eliminating waste and meeting the demanding expectations of global regulators. Its DMAIC and DMADV cycles, supported by tools such as SPC, FMEA, RCA and DoE, map directly onto the ICH Q8–Q12 framework, onto FDA process-validation expectations and onto the practical mechanics of CAPA. Successful implementation, however, depends on more than technical proficiency: it requires leadership commitment, investment in data infrastructure, alignment with existing quality systems, and the discipline to sustain gains beyond project closure. As pharmaceutical manufacturing converges with PAT-enabled continuous processing and Industry 4.0 data architectures, the role of Six Sigma is likely to evolve from a discrete improvement methodology into an embedded property of the quality system, in which CTQ-driven design, statistically controlled execution, and continuous learning are inseparable from compliance itself.
1. U.S. Food and Drug Administration. Code of Federal Regulations Title 21, Parts 210 and 211: Current Good Manufacturing Practice for Finished Pharmaceuticals. Silver Spring (MD): FDA; updated 2023.
2. European Commission. EudraLex Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Brussels: European Commission; 2022.
3. International Council for Harmonisation. ICH Q10: Pharmaceutical Quality System. Geneva: ICH; 2008.
4. Pyzdek T, Keller P. The Six Sigma Handbook. 5th ed. New York: McGraw-Hill Education; 2018.
5. Antony J, Lizarelli FL, Fernandes MM, Dempsey M, Brennan A, McFarlane J. A study into the reasons for process improvement project failures: results from a pilot survey. Int J Qual Reliab Manag. 2019; 36(10): 1699–1720. doi:10.1108/IJQRM-03-2019-0093.
6. Snee RD. Lean Six Sigma—getting better all the time. Int J Lean Six Sigma. 2010; 1(1): 9–29. doi:10.1108/20401461011033130.
7. International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. Geneva: ICH; 2009.
8. International Council for Harmonisation. ICH Q9(R1): Quality Risk Management. Geneva: ICH; 2023.
9. International Council for Harmonisation. ICH Q10: Pharmaceutical Quality System. Geneva: ICH; 2008.
10. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical Quality by Design. AAPS J. 2014; 16(4): 771–783. doi:10.1208/s12248-014-9598-3.
11. Trubetskaya A, Manto D, McDermott O. A review of Lean adoption in the Irish MedTech industry. Processes. 2022; 10(2): 391. doi:10.3390/pr10020391.
12. Sreedharan VR, Sandhya G, Raju R. Development of a Green Lean Six Sigma model for public sectors. Int J Lean Six Sigma. 2018;9(2):238–255. doi:10.1108/IJLSS-02-2017-0020.
13. George ML. Lean Six Sigma: Combining Six Sigma Quality with Lean Production Speed. New York: McGraw-Hill; 2002.
14. Harry M, Schroeder R. Six Sigma: The Breakthrough Management Strategy Revolutionising the World’s Top Corporations. New York: Doubleday; 2000.
15. Montgomery DC. Introduction to Statistical Quality Control. 8th ed. Hoboken (NJ): Wiley; 2019.
16. U.S. Food and Drug Administration. Guidance for Industry: Process Validation—General Principles and Practices. Silver Spring (MD): FDA; 2011.
17. Schroeder RG, Linderman K, Liedtke C, Choo AS. Six Sigma: definition and underlying theory. J Oper Manag. 2008; 26(4): 536–554. doi:10.1016/j.jom.2007.06.007.
18. Charde MS, Welankiwar AS, Kumar J. Six Sigma: a novel approach to pharmaceutical industry. Int J Adv Pharm Anal. 2014; 4(3): 92–97.
19. Gupta V, Rathore GS. Six Sigma in pharmaceutical industry and regulatory affairs: a review. J Nat Conscientia. 2011; 2(2): 324–333.
20. Antony J. Six Sigma vs Lean: some perspectives from leading academics and practitioners. Int J Product Perform Manag. 2011;60(2):185–190. doi:10.1108/17410401111101494.
21. Pyzdek T, Keller P. The Six Sigma Handbook. 5th ed. New York: McGraw-Hill; 2018.
22. AIAG. Measurement Systems Analysis (MSA) Reference Manual. 4th ed. Southfield (MI): Automotive Industry Action Group; 2010.
23. Antony J, Sony M, Furterer S, McDermott O, Pepper M. Quality 4.0 and its impact on organisational performance: an integrative viewpoint. TQM J. 2022;34(6):2069–2084. doi:10.1108/TQM-08-2021-0242.
24. Stamatis DH. Failure Mode and Effect Analysis: FMEA from Theory to Execution. 3rd ed. Milwaukee (WI): Quality Press; 2019.
25. Snee RD, Hoerl RW. Leading Six Sigma: A Step-by-Step Guide Based on Experience with GE and Other Six Sigma Companies. Upper Saddle River (NJ): FT Press; 2018.
26. Yang K, El-Haik B. Design for Six Sigma: A Roadmap for Product Development. 2nd ed. New York: McGraw-Hill; 2018.
27. Womack JP, Jones DT. Lean Thinking: Banish Waste and Create Wealth in Your Corporation. Revised ed. New York: Free Press; 2003.
28. Liker JK. The Toyota Way. 2nd ed. New York: McGraw-Hill; 2021.
29. Woodall WH, Montgomery DC. Some current directions in the theory and application of statistical process monitoring. J Qual Technol. 2014; 46(1): 78–94. doi:10.1080/00224065.2014.11917955.
30. Wilkinson L. Revising the Pareto chart. Am Stat. 2006; 60(4): 332–334. doi:10.1198/000313006X152243.
31. International Council for Harmonisation. ICH Q9(R1): Quality Risk Management. Geneva: ICH; 2023.
32. Reddy A, Nagpal D, Saxena S. Six Sigma approach to pharmaceutical industry: a better insight. Orient J Chem. 2024; 40(5): 1287–1298. doi:10.13005/ojc/400502.
33. Politis SN, Colombo P, Colombo G, Rekkas DM. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017; 43(6): 889–901. doi:10.1080/03639045.2017.1291672.
34. Rother M, Shook J. Learning to See: Value-Stream Mapping to Create Value and Eliminate Muda. Cambridge (MA): Lean Enterprise Institute; 2003.
35. Doshi JA, Desai DA. Application of failure modes and effects analysis (FMEA) for continuous quality improvement—multiple case studies in automobile SMEs. Int J Qual Reliab Manag. 2017; 34(4): 572–588.
36. Patel A, Lalwani D, Patel V. Implementation of Six Sigma in pharmaceutical manufacturing—a case study of tablet weight variation. Int J Pharm Sci Res. 2020; 11(5): 2156–2163.
37. Yu LX, Kopcha M. The future of pharmaceutical quality and the path to get there. Int J Pharm. 2017; 528(1–2): 354–359. doi:10.1016/j.ijpharm.2017.06.039.
38. McDermott O, Antony J, Sony M, Healy T. Critical failure factors for Continuous Improvement methodologies in the Irish MedTech industry. TQM J. 2022; 34(7): 18–38. doi:10.1108/TQM-10-2021-0289.
39. Juran JM, Godfrey AB. Juran’s Quality Handbook. 7th ed. New York: McGraw-Hill; 2017.
40. Friedman RL. FDA inspection observations: the top deficiencies. PDA J Pharm Sci Technol. 2018; 72(3): 243–256. doi:10.5731/pdajpst.2017.008060.
41. Nour R, Laux C. Application of Lean Six Sigma to reduce the cost of regulatory non-compliance. J Manag Sci Eng. 2019; 4(2): 85–98.
42. Vest JR, Gamm LD. A critical review of the research literature on Six Sigma, Lean and Studer Group’s Hardwiring Excellence in the United States: the need to demonstrate and communicate the effectiveness of transformation strategies in healthcare. Implement Sci. 2009; 4(1): 35. doi:10.1186/1748-5908-4-35.
43. Markarian J. Implementing Industry 4.0 in pharma manufacturing. Pharm Technol. 2021; 45(3): 44–46.
44. Antony J, Sony M, Dempsey M, Brennan A, Farrington T, Cudney EA. An evaluation into the limitations and emerging trends of Six Sigma: an empirical study. TQM J. 2019; 31(2): 205–221. doi:10.1108/TQM-12-2018-0191.
45. Lee SL, O’Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov. 2015; 10(3): 191–199. doi:10.1007/s12247-015-9215-8.
46. Burcham CL, Florence AJ, Johnson MD. Continuous manufacturing in pharmaceutical process development and manufacturing. Annu Rev Chem Biomol Eng. 2018; 9: 253–281. doi:10.1146/annurev-chembioeng-060817-084355.
47. Sahu S, Mishra B. Machine learning and pharmaceutical manufacturing. AAPS PharmSciTech. 2024; 25(1): 17. doi:10.1208/s12249-023-02723-4.
|
Received on 26.05.2026 Revised on 12.06.2026 Accepted on 27.06.2026 Published on 04.07.2026 Available online from July 30, 2026 Asian J. Research Chem.2026; 19(4):370-376. DOI: 10.52711/0974-4150.2026.00056 ©A and V Publications All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License. |
|